Thorel Marine, Fummi Camille, Gras Valérie, Masmoudi Kamel
Centre de biologie humaine, centre régional de pharmacovigilance de Picardie, centre hospitalier universitaire d'Amiens, 80054 Amiens cedex 1, France.
Centre de biologie humaine, centre régional de pharmacovigilance de Picardie, centre hospitalier universitaire d'Amiens, 80054 Amiens cedex 1, France.
Therapie. 2016 Jun;71(3):323-8. doi: 10.1016/j.therap.2015.11.004. Epub 2016 Feb 11.
Twenty-two cases related to benzodiazepine (BZD) withdrawal syndrome were identified and reported to Amiens's regional pharmacovigilance center between January 1st, 1995 and March 25th, 2014, all with a favourable outcome after reintroduction of a BZD. Despite being a very classical well-known side effect, physicians may underestimate this risk. Our series also confirms that the patient is misinformed about the consequences of an abrupt BZD discontinuation especially when the BZD has been consumed for many years. Interviewing patient and his family on the nature of the current medical treatments should be systematic and an early diagnostic step taken by physicians faced with a recent behavioral disorder. Moreover, this would prevent unnecessary, sometimes invasive, expensive investigations and a prolonged hospitalization.
1995年1月1日至2014年3月25日期间，共识别出22例与苯二氮䓬（BZD）戒断综合征相关的病例，并报告给了亚眠地区药物警戒中心，所有病例在重新使用BZD后均取得了良好疗效。尽管这是一种非常典型的已知副作用，但医生可能会低估这种风险。我们的系列病例还证实，患者对突然停用BZD的后果了解有误，尤其是当BZD已服用多年时。面对近期出现行为障碍的患者，医生应系统地询问患者及其家属当前的治疗情况，并尽早进行诊断。此外，这将避免不必要的、有时是侵入性的、昂贵的检查以及延长住院时间。
